Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection.

Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection.
复制标题

DOI:
10.3390/pharmaceutics13071077
复制
发表时间:
2021-07-14
期刊:
影响因子:
5.4
通讯作者:
Mansour HM
Mansour HM
中科院分区:
医学2区
文献类型:
--
作者:
Eedara BB;Alabsi W;Encinas-Basurto D;Polt R;Ledford JG;Mansour HM

文献摘要

参考文献

被引文献

相似文献

2019 冠状病毒病 (COVID-19) 由冠状病毒 2 (SARS-CoV-2) 引起,并已造成全球大流行。截至 2021 年 6 月 22 日,全球有 1.78 亿人受到感染,387 万人死于 COVID-19。据美国疾病控制与预防中心(CDC)称,COVID-19病毒主要通过呼吸道飞沫和接触途径在人与人之间传播。由于最初感染和疾病进展的部位主要是通过肺部,因此将药物直接吸入肺部可能是治疗 COVID-19 的最合适的给药途径。本文旨在介绍治疗 COVID-19 症状的可能的吸入疗法和疫苗。本综述涵盖了 SARS-CoV-2 与其他冠状病毒(例如 SARS-CoV/MERS)之间的比较、治疗 COVID-19 症状的吸入疗法和预防感染的疫苗,以及吸入疗法和疫苗的当前临床状况。
Coronavirus disease-2019 (COVID-19) is caused by coronavirus-2 (SARS-CoV-2) and has produced a global pandemic. As of 22 June 2021, 178 million people have been affected worldwide, and 3.87 million people have died from COVID-19. According to the Centers for Disease Control and Prevention (CDC) of the United States, COVID-19 virus is primarily transmitted between people through respiratory droplets and contact routes. Since the location of initial infection and disease progression is primarily through the lungs, the inhalation delivery of drugs directly to the lungs may be the most appropriate route of administration for treating COVID-19. This review article aims to present possible inhalation therapeutics and vaccines for the treatment of COVID-19 symptoms. This review covers the comparison between SARS-CoV-2 and other coronaviruses such as SARS-CoV/MERS, inhalation therapeutics for the treatment of COVID-19 symptoms, and vaccines for preventing infection, as well as the current clinical status of inhaled therapeutics and vaccines.
DOI: 10.1371/journal.pone.0246803
发表时间: 2021
期刊: PloS one
影响因子: 3.7
作者:
Brunaugh AD;Seo H;Warnken Z;Ding L;Seo SH;Smyth HDC
通讯作者: Smyth HDC
DOI: 10.1164/rccm.201312-2235oc
发表时间: 2014-07-15
影响因子: 24.7
作者:
Djukanovic, Ratko;Harrison, Tim;Monk, Phillip
通讯作者: Monk, Phillip
DOI: 10.1016/j.addr.2020.12.011
发表时间: 2021-03
影响因子: 16.1
作者:
Chung JY;Thone MN;Kwon YJ
通讯作者: Kwon YJ
DOI: 10.1016/j.antiviral.2020.104787
发表时间: 2020-06-01
期刊: Antiviral research
影响因子: 7.6
作者:
Caly, Leon;Druce, Julian D;Wagstaff, Kylie M
通讯作者: Wagstaff, Kylie M
DOI: 10.1016/j.ejps.2019.104961
发表时间: 2019-08-01
影响因子: 4.6
作者:
Eedara, Basanth Babu;Tucker, Ian G.;Das, Shyamal C.
通讯作者: Das, Shyamal C.